NDAORALTABLETPriority Review
Approved
Mar 2018
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
SYMFI (efavirenz, lamivudine and tenofovir disoproxil fumarate) by Viatris is non-nucleoside reverse transcriptase inhibitors [moa]. First approved in 2018.
Drug data last refreshed 47m ago · AI intelligence enriched 3h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SYMFI is a fixed-dose combination tablet containing efavirenz, lamivudine, and tenofovir disoproxil fumarate for the treatment of HIV-1 infection. It works by inhibiting reverse transcriptase, a key enzyme in HIV replication. This oral tablet is designed as a simplified, once-daily regimen for treatment-naïve and treatment-experienced patients.
$0.001BPart D
PeakProduct is at peak lifecycle stage with modest Medicare utilization; commercial teams should expect stable but not expanding headcount or marketing budgets.
Mechanism of Action
Non-Nucleoside Reverse Transcriptase Inhibitors
Pharmacologic Class:
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SYMFI offers career opportunities primarily in commercial and market access functions within a mature, stable therapeutic category. Roles on this product emphasize maintaining market position and managing payer relationships in a crowded HIV treatment landscape rather than driving growth.
Brand Manager
Worked on SYMFI at Viatris? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.